

=====

SECURITIES AND EXCHANGE COMMISSION  
 WASHINGTON, D.C. 20549

-----

SCHEDULE 14D-1  
 (Amendment No. 2/Final Amendment)

AND  
 SCHEDULE 13D  
 TENDER OFFER STATEMENT  
 PURSUANT TO SECTIONS 13(D) AND 14(D)(1)  
 OF THE SECURITIES EXCHANGE ACT OF 1934

-----

ISOMEDIX INC.  
 (Name of Subject Company [Issuer])

STERIS ACQUISITION CORPORATION  
 STERIS CORPORATION  
 (Bidders)

COMMON STOCK, PAR VALUE \$.01 PER SHARE  
 (Including the Associated Preferred Stock Purchase Rights)  
 (Title of Class of Securities)

464890102  
 (CUSIP Number of Class of Securities)

-----

BILL R. SANFORD  
 STERIS ACQUISITION CORPORATION  
 C/O STERIS CORPORATION  
 5960 HEISLEY ROAD  
 MENTOR, OHIO 44060  
 TELEPHONE: (216) 354-2600

(Name, Address and Telephone Number of Person  
 Authorized to Receive Notices and Communications on Behalf of Bidders)

-----

Copy to:  
 ROY L. TURNELL, ESQ.  
 THOMPSON HINE & FLORY LLP  
 3900 KEY CENTER  
 127 PUBLIC SQUARE  
 CLEVELAND, OHIO 44114-1216  
 TELEPHONE: (216) 566-5500

CALCULATION OF FILING FEE

TRANSACTION VALUATION*	AMOUNT OF FILING FEE
\$ 155,470,401.00	\$ 31,094.08

\* For purposes of calculating fee only. This amount assumes the purchase at a purchase price of \$20.50 per share of an aggregate of 7,583,922 shares of common stock. The amount of the filing fee, calculated

in accordance with Regulation 240.0-11 of the Securities Exchange Act of 1934, as amended, equals 1/50th of one percentum of the value of shares purchased.

[X] Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$31,094.08

Filing Party: STERIS Acquisition Corporation and STERIS Corporation

Form or Registration No:  
Schedule 14D-1 Tender Offer Statement

Date Filed: August 18, 1997

=====

1. NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

STERIS Acquisition Corporation

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]  
(b) [ ]

3. SEC USE ONLY

4. SOURCE OF FUNDS

AF

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO  
ITEM 2(e) or 2(f) [ ]

6. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

7. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,263,670 shares\*\*

8. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES CERTAIN SHARES [ ]

9. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7)

95.7%\*\*

10. TYPE OF REPORTING PERSON

CO

-----  
 1. NAME OF REPORTING PERSONS  
 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS  
  
 STERIS Corporation  
 -----

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]  
 (b) [ ]  
 -----

3. SEC USE ONLY  
 -----

4. SOURCE OF FUNDS  
  
 BK  
 -----

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO  
 ITEM 2(e) or 2(f) [ ]  
 -----

6. CITIZENSHIP OR PLACE OF ORGANIZATION  
  
 Ohio  
 -----

7. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
  
 6,263,670 shares\*\*  
 -----

8. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES CERTAIN SHARES [ ]  
 -----

9. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7)  
  
 95.7%\*\*  
 -----

10. TYPE OF REPORTING PERSON  
  
 CO  
 -----

\*\* Reflects ownership of the shares of common stock of Isomedix Inc. after the purchase by STERIS Acquisition Corporation of shares tendered pursuant to the tender offer, but prior to the completion of the merger of STERIS Acquisition Corporation with and into Isomedix Inc. as disclosed below. After completion of the merger, STERIS Corporation owned 100% of the outstanding shares of common stock of Isomedix Inc. See Item 6.

STERIS Acquisition Corporation (the "Purchaser"), a Delaware corporation and a wholly owned subsidiary of STERIS Corporation, an Ohio corporation (the "Parent"), and the Parent hereby amend and supplement their Tender Offer Statement on Schedule 14D-1, as heretofore amended (the "Schedule 14D-1"), relating to the Purchaser's offer to purchase all of the outstanding shares of common stock, par value \$.01 per share, and the associated preferred stock purchase rights (together with the rights, the "Shares") of Isomedix Inc., a Delaware corporation (the "Company"), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated August 18, 1997 (the "Offer to Purchase"), and in the related Letter of Transmittal (which, as amended from time to time, together constitute the "Offer"). This Statement is also being filed on behalf of the Parent and the Purchaser for purposes of Schedule 13D of the Securities Exchange Act of 1934, as amended. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Schedule 14D-1 or the Offer to Purchase filed as an exhibit thereto.

ITEM 5. PURPOSE OF THE TENDER OFFER AND PLANS OR PROPOSALS OF THE BIDDERS.

On September 17, 1997, the Merger was effected through a "short form" merger under Delaware law by action of the Purchaser's Board of Directors.

ITEM 6. INTEREST IN SECURITIES OF THE SUBJECT COMPANY.

The Offer expired at 12:00 midnight, Eastern Daylight Saving Time, on Tuesday, September 16, 1997. According to the Depositary for the Offer, a total of approximately 6,263,670 Shares (including approximately 207,804 Shares subject to guarantees of delivery) were tendered pursuant to the Offer. All properly tendered Shares were purchased on September 17, 1997 in accordance with the terms of the Offer. The Shares tendered and purchased constitute approximately 95.7% of the outstanding Shares.

At the Effective Time of the Merger, the Parent became the owner of 100% of the outstanding shares of common stock of the Company.

The information set forth in Exhibit (a)(9) is incorporated herein by reference.

ITEM 10. ADDITIONAL INFORMATION.

At the Effective Time of the Merger and pursuant to the Merger Agreement, the directors and officers of the Purchaser became the directors and officers of the Company.

ITEM 11. MATERIAL TO BE FILED AS EXHIBITS.

(a)(9) Press Release, dated September 17, 1997.

SIGNATURES

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: September 19, 1997

STERIS ACQUISITION CORPORATION

By: /s/ BILL R. SANFORD

-----  
Name: Bill R. Sanford  
Title: Chairman, President, and  
Chief Executive Officer

STERIS CORPORATION

By: /s/ BILL R. SANFORD

-----  
Name: Bill R. Sanford  
Title: Chairman, President, and  
Chief Executive Officer

EXHIBIT INDEX

Exhibit  
Number  
-----

Exhibit Name  
-----

(a)(9)

Press Release, dated September 17, 1997.

PRESS RELEASE  
FOR IMMEDIATE RELEASE

[STERIS LOGO]

CONTACTS: Michael A. Keresman, III, Senior Vice President and CFO  
Gerard J. Reis, Vice President Business and Professional Relations  
(216) 354-2600

STERIS CORPORATION CLOSES  
TENDER OFFER FOR ISOMEDIX STOCK

Mentor, Ohio (Wednesday, September 17, 1997) -- STERIS Corporation (NASDAQ:STRL) and Isomedix, Inc. (NYSE:ISO) today jointly announced that the tender offer of STERIS, through its wholly-owned subsidiary STERIS Acquisition Corporation for all the outstanding shares of common stock of Isomedix at a price of \$20.50 per share, expired at 12:00 midnight, on Tuesday, September 16, 1997. According to the depository for the offer, 6,263,670 shares, representing approximately 96% of the issued and outstanding shares of Isomedix, were tendered pursuant to the offer (including approximately 207,804 shares subject to guarantees of delivery). STERIS has notified the depository that it will purchase all shares tendered.

STERIS plans to promptly effect the merger of STERIS Acquisition Corporation into Isomedix. In the merger each remaining outstanding share of Isomedix will be converted into the right to receive \$20.50 net in cash and Isomedix will become a wholly-owned subsidiary of STERIS.

Isomedix provides contract sterilization and microbial reduction services to manufacturers of pre-packaged products, including healthcare and consumer products, through a network of eleven gamma facilities and five ethylene oxide facilities (four of which are combined gamma/ethylene oxide) in the United States, Canada, and Puerto Rico. A new electron-beam facility in Illinois is scheduled to begin operations later this year.

STERIS Corporation is a leading provider of infection prevention, contamination prevention, and surgical support systems, products, services, and technologies to healthcare, scientific, research, and industrial Customers throughout the world. Customer Support facilities are located in major global market centers with manufacturing operations in the United States, Canada, Germany, and Finland.

(end)